Malin Corporation
Venture Capital
Active
Dublin, United Kingdom
16
56M
10
1.78
6
0.38
5
- Areas of investment
Summary
Malin Corporation is the famous Corporate Investor, which was founded in 2014. The fund was located in Europe if to be more exact in Ireland. The main department of described Corporate Investor is located in the Dublin.
Among the most popular fund investment industries, there are Medical, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Xenex, Artizan Biosciences, 3D4Medical.com. The fund has exact preference in a number of founders of portfolio startups. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.
Deals in the range of 50 - 100 millions dollars are the general things for fund. The real fund results show that this Corporate Investor is 38 percentage points more often commits exit comparing to other companies. Opposing the other organizations, this Malin Corporation works on 21 percentage points less the average amount of lead investments. The high activity for fund was in 2015. The higher amount of exits for fund were in 2019. The fund is generally included in 2-6 deals every year. The average startup value when the investment from Malin Corporation is 10-50 millions dollars.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Malin Corporation, startups are often financed by Wellcome Trust, Targeted Technology Fund, RK Ventures Group. The meaningful sponsors for the fund in investment in the same round are Woodford Investment Management, Vivo Capital, Longitude Capital. In the next rounds fund is usually obtained by Vivo Capital, Longitude Capital, Bill & Melinda Gates Foundation.
Investor highlights
- Industry focus
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 16
- Lead investments
- 6
- Exits
- 5
- Rounds per year
- 1.78
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (14)
- Health Care (9)
- Therapeutics (6)
- Genetics (4)
- Biopharma (4) Show 13 more
- Investments by region
-
- United States (12)
- United Kingdom (3)
- Ireland (1)
- Peak activity year
- 2015
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 12
- Avg. valuation at time of investment
- 208M
- Group Appearance index
- 0.62
- Avg. company exit year
- 12
- Avg. multiplicator
- 1.34
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
Kymab | 24 Nov 2016 | Biotechnology, Drug Discovery, Pharmaceuticals, Therapeutics, Biopharma | Late Stage Venture | 100M | Cambridge, United Kingdom, England |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.